SCHEMBL6489702

SCHEMBL6489702

NCCNC(=O)c1cc2ccc(NC(=O)c3cccc(C(=O)Nc4ccc5cc(C(=O)NCCN)[nH]c5c4)n3)cc2[nH]1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.52
HSD17B10 Q99714 1/20 0.52
ALOX15 P16050 4/20 0.48
ALDH1A1 P00352 1/20 0.44
DRD2 P14416 1/20 0.44
DRD3 P35462 1/20 0.44
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43
HDAC3 O15379 2/20 0.43
HDAC1 Q13547 2/20 0.43
AKR1C3 P42330 1/20 0.43
HTR2C P28335 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5889851 0.91 KDM4E (0.52) KDM4EHSD17B10ALDH1A1ITGB3ITGA2B
SCHEMBL5889563 0.87 KDM4E (0.53) KDM4EHSD17B10ALOX15ALDH1A1DRD2
SCHEMBL5889774 0.86 KDM4E (0.46) KDM4EHSD17B10ALOX15ALDH1A1DRD2
SCHEMBL5889467 0.84 KDM4E (0.45) KDM4EHSD17B10ALOX15ITGB3ITGA2B
SCHEMBL5896655 0.81 KDM4E (0.51) KDM4EHSD17B10ITGB3ITGA2B
SCHEMBL5889537 0.81 KDM4E (0.51) KDM4EHSD17B10ITGB3ITGA2B
SCHEMBL5889522 0.78 KDM4E (0.53) KDM4EHSD17B10ITGB3ITGA2B
SCHEMBL5889557 0.77 KDM4E (0.46) KDM4EHSD17B10ALDH1A1ITGB3ITGA2B
SCHEMBL6500694 0.75 HRH4 (0.47) KDM4EHSD17B10ITGB3ITGA2B
Hydrochloric Acid SCHEMBL20267092 0.75 KDM4E (0.82) KDM4EHSD17B10ALDH1A1DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906103-B2 Compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. (US) 2005-06-14 US disclosed
US-6849713-B2 Compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. (US) 2005-02-01 US disclosed
WO-2003057212-A1 POLYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECHNOLOGIES, INC. (US) 2003-07-17 WO disclosed
US-20030119749-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity SMITHKLINE BEECHAM CORPORATION 2003-06-26 US disclosed
EP-1294713-A2 COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECHNOLOGIES, INC. (US) 2003-03-26 EP disclosed
WO-2002000650-A9 NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECH INC (US) 2003-03-06 WO disclosed
US-20020037856-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. 2002-03-28 US disclosed
WO-2002000650-A2 NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECHNOLOGIES, INC. (US) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119749-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity CYP51A1, MCL1, ERG28 KDM4E 3560/4885HSD17B10 2227/4885ALOX15 1998/4885
US-20020037856-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity CYP51A1, MCL1, ERG28 KDM4E 3560/4885HSD17B10 2227/4885ALOX15 1998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.